ArticleFrontiers in immunology2026
AI-guided epitope engineering of a SARS-CoV-2 spike antigen for broad sarbecovirus neutralization.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid evolution of SARS-CoV-2 and the ongoing risk of zoonotic spillover highlight the need for vaccines that provide broad protection beyond strain-specific immunity. Here, we present a structure-guided, AI-enabled strategy for rational antigen design that enhances cross-reactive B-cell epitope recognition across betacoronaviruses. By integrating comparative sequence analysis with conformational epitope prediction, we identified conserved epitope hotspots within the Spike receptor-binding domain and introduced targeted motif-level substitutions into a SARS-CoV-2 BA.2 backbone. Engineered Spike immunogens, delivered as mRNA-lipid nanoparticle vaccines, elicited robust antibody responses in mice and demonstrated broad neutralizing activity against antigenically diverse SARS-CoV-2 variants, including BA.5 and XBB.1.5, as well as zoonotic sarbecoviruses. Selected designs reached neutralisation breadth comparable to an Omicron-adapted clinical benchmark for shared SARS-CoV-2 antigens, while extending neutralising activity to divergent zoonotic sarbecoviruses. These findings show that minimal, structure-guided epitope remodeling can enhance the presentation of conserved epitopes and improve antibody breadth, providing a generalizable framework for designing vaccines resilient to viral evolution and future pandemic threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.